Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. What are the treatments for aplastic anemia?

    ... blood transfusions and antibiotics and for certain patients, growth factors or iron chelation. Immunosuppressive therapy:  Works to ... aplastic anemia. This drug is a platelet growth factor , but seems to stimulate growth of red cells and white cells too. ...

    FAQ last updated 01/04/2018 - 12:29pm.

  2. Revisiting use of growth factors in myelodysplastic syndromes

    ... with a high IPSS score. The advent of use of hematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF) and recombinant erythropoietin (EPO) has improved ...

    Research Article last updated 07/31/2012 - 12:57pm.

  3. Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes

    ... that erlotinib has in vivo and in vitro off epidermal growth factor receptor (EGFR)-target activity in MDS. We conducted a phase II ...

    Research Article last updated 05/22/2014 - 10:33am.

  4. Myelodysplastic syndromes: therapy and outlook

    ... has been further enhanced with immunosuppressive agents, growth factor support, and biologic response modifiers. Initial treatment ...

    Research Article last updated 07/31/2012 - 1:27pm.

  5. Azacitidine adverse effects in patients with myelodysplastic syndromes

    ... causes hematological toxicity that is managed with growth factor support, blood transfusions, and dose and schedule adjustment. ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

    ... prolong survival. Current available therapies include growth factor support, lenalidomide , hypomethylating agents, intensive ...

    Research Article last updated 02/04/2014 - 1:37pm.

  7. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... to prolong survival. Current available therapies include growth factor support, lenalidomide , hypomethylating agents, intensive ...

    Research Article last updated 07/31/2012 - 2:02pm.

  8. Prediction of adverse events during Intensive Induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes

    ... our studies identify severe baseline neutropenia as a risk factor for infection-associated adverse events after induction chemotherapy and ... the rationale for the risk-adapted testing of myeloid growth factor support in this high-risk AML/MDS patient subset. ...

    Research Article last updated 01/07/2014 - 12:42pm.

  9. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... to prolong survival. Current available therapies include growth factor support, lenalidomide , hypomethylating agents, intensive ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes.

    ... thrombopoietin and granulocyte colony-stimulating factor, with low levels of CD40 ligand, chemokine (C-X-C motif) ligand 5, ... ligand 5, chemokine (C-X-C motif) ligand 11, epidermal growth factor , vascular endothelial growth factor, and chemokine (C-C ...

    Research Article last updated 10/11/2011 - 5:58pm.